Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Subcutaneous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Bosnia | Brazil | Croatia | India | Ireland | Taiwan | Thailand | Turkey | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: M.D. Anderson Cancer Center
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Other
Phase 2: Hereditary Sensory and Autonomic Neuropathies|Acute Myeloid Leukemia|Peripheral Nervous System Diseases|Amyotrophic Lateral Sclerosis|Pleural Cancer|Mesothelioma|Non-Small-Cell Lung Cancer|Carcinoma, Merkel Cell|Alzheimer Disease|Adenocarcinoma|Pancreatic Cancer|Chronic Myelomonocytic Leukemia|Myeloid, Accelerated Leukemia|Acute Megakaryoblastic Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Monocytic Leukemia|Chronic Myeloid Leukemia|Blast Crisis|Preleukemia|Juvenile Myelomonocytic Leukemia,|Acute Erythroblastic Leukemia|Acute Myelomonocytic Leukemia|Myelodysplastic Syndrome
Phase 1: Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified|Sarcoma|Graft vs Host Disease|Stem Cell Transplant
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SENSE | P2 |
Recruiting |
Hereditary Sensory and Autonomic Neuropathies |
2025-08-01 |
|
| 2022-000241-32 | P3 |
Active, not recruiting |
Other |
2025-06-30 |
|
| FATHIS+ | N/A |
Not yet recruiting |
Fatty Liver, Alcoholic|Liver Diseases, Alcoholic|Non-alcoholic Fatty Liver Disease|Obesity, Abdominal |
2025-05-01 |
|
| ACTRN12619000561189 | N/A |
Recruiting |
Hereditary Sensory Neuropathy Type 1 |
2024-12-31 |